Lung cancer has a high incidence rate and a low cure rate, hence the urgent need for effective treatment methods. Current lung cancer drugs have several drawbacks, including low specificity, poor targeting, drug resistance, and irreversible damage to normal tissues. Therefore, there is a need to develop a safe and effective new drug that can target and kill tumor cells. In this study, we combined nanotechnology and biotechnology to develop a CD133 ligand‐modified etoposide‐liposome complex (Lipo@ETP‐CD133) for targeted therapy of lung cancer. The CD133 ligand targeted lung cancer stem cells, causing the composite material to aggregate at the tumor site, where high levels of ETP liposomes could exert a strong tumor‐killing effect. Our research results demonstrated that this nano‐drug had efficient targeting and tumor‐killing effects, indicating its potential for clinical application.

中文翻译：

---

CD133配体增强依托泊苷脂质体复合物靶向杀伤肺癌细胞

肺癌发病率高，治愈率低，迫切需要有效的治疗方法。目前的肺癌药物存在特异性低、靶向性差、耐药性以及对正常组织造成不可逆损伤等缺点。因此，需要开发一种安全有效、能够靶向杀伤肿瘤细胞的新药。在本研究中，我们结合纳米技术和生物技术开发了一种CD133配体修饰的依托泊苷-脂质体复合物（Lipo@ETP-CD133），用于肺癌的靶向治疗。 CD133配体靶向肺癌干细胞，导致复合材料聚集在肿瘤部位，高水平的ETP脂质体可以发挥强大的肿瘤杀伤作用。我们的研究结果表明，这种纳米药物具有高效的靶向和杀伤作用，显示出其临床应用的潜力。